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Abstract 
The impact of COVID-19 has been, and continues to be, felt across the world.  For some 
people the risks associated with contracting this virus are greater than others due to 
underlying health conditions. This article explores the impact of COVID-19 for people with 
Parkinson’s and how specialist health services are having to change to continue to support 
this group of patients.    
 
Over the last few weeks, our world has changed beyond recognition due to the COVID-19 
pandemic. Many specialist nurses have been redeployed to different clinical areas to support 
front line staff, while those left managing specialist services have had to rapidly redesign and 
adjust ways of working. This article explores the impact that COVID-19 is currently having on 
people with Parkinson’s Disease (PD) (Figure 1) and how services they rely on to manage 
their complex long-term neurological condition have changed.  
The risk of Covid-19 for people with Parkinson’sCOVID-19 is a newly discovered 
coronavirus (coronavirus 2 (SARS-CoV-2)) and is a highly infectious viral disease that was 
first reported in Wuhan, China at the end of December 2019. Due to the alarming level of 
spread and severity the World Health Organisation (WHO) characterised COVID-19 as a 
global pandemic on 11 March 2020. For many, COVID-19 has a clinical presentation similar 
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to influenza, typically with fatigue, fever, hyposmia, loss of taste and non-productive cough 
(Chen et al, 2020; Guan and Zhong, 2020). Diarrhoea has been a reported symptom, which 
could indicate initial infection through the gastrointestinal tract. Neurological symptoms, such 
as headache and nausea, can also occur for some people contracting the virus (Carod-Artal, 
2020). Coronaviruses, including COVID-19, are likely to be neurotropic with spread via the 
lingual or olfactory nerves, as anosmia/hyposmia and ageusia is reported in many infected 
patients, a symptomatology that closely resembles one of the most prominent pre-motor 
symptoms of PD (Schaeffer et al, 2020). Most infected patients (approximately 80%) 
experience a mild clinical form and recover without complications (Huang et al, 2020) Wang 
et al, 2020). For some, particularly those considered to be most at risk, symptoms of COVID-
19 can be much more severe, resulting in severe respiratory difficulties, pneumonia and end-
stage intravascular coagulation (Chaudhuri, 2020).   
By 15 April 2020, the Department of Health and Social Care (DHSC) in England stated that 
all people should ‘Stay at home, protect the NHS, save lives’. Further recommendations 
were given to people aged 70 or over, or those with an underlying health condition, to stay at 
home at all times, avoiding leaving to even buy food, collect medicine or exercise until at 
least the end of June 2020. People at high risk, and described as clinically extremely 
vulnerable, were contacted via the NHS and provided with extra support to ensure they were 
able to remain at home. Although people with PD have not been classified as ‘extremely 
vulnerable’, they are classified as ‘moderately vulnerable’, which means they should only 
leave their home to buy food or medicine or exercise once daily. There is reasonable 
evidence stemming from basic science and immunological science that people with PD are 
at greater risk of developing COVID-19, and there is evidence to suggest they may have 
more severe symptoms if they do contract the virus. A potential relationship of coronavirus 
and clinical consequences with relevance to PD was reported almost 20 years previously 
(Fazzini et al, 1992). People who are older with more advanced PD may represent a 
particularly vulnerable population due to respiratory muscle rigidity, as well as possibly brain 
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stem involvement related impairment of cough reflex alongside pre-existing dyspnoea, may 
lead to increased severity of COVID-19 infection (van Wamelen et al, 2020a). These 
features of PD increase the chance of developing aspiration pneumonia, which is cited as a 
well-known cause of mortality in PD (Kalf et al, 2012). A recent paper by Antonini et al, 
(2020) reported the first series of ten cases of people with PD and COVID-19-positive and 
found that those of older age (mean 78.3 years) with longer disease duration (mean 12.7 
years) were particularly susceptible to COVID-19, with a substantially high mortality rate 
(40%). Those on advanced therapies, such as deep brain stimulation or levodopa infusion 
therapy, seem especially vulnerable; with a mortality rate of 50% among the four such 
cases, this is a cause for concern (Antonini et al, 2020). 
For those people with PD who are severely affected with pneumonia, possibly needing 
ventilation, or for those at end of life, a strategy for the use of non-oral dopaminergic drugs 
needs to be implemented (Antonini et al, 2020; Chaudhuri, 2020). Non-oral dopaminergic 
therapies will also need to be considered if swallowing becomes unsafe and nil by mouth is 
recommended or if diarrhoea is present, as oral PD medication may not be efficacious. This 
may mean liquid levodopa via a PEG or nasogastric tube, use of transdermal rotigotine 
patches, or apomorphine injection or infusion (with careful monitoring of potential side 
effects), so that dopamine agonist or levodopa withdrawal syndrome can be avoided and 
worsening motor and nonmotor symptoms of PD are avoided (Chaudhuri, 2020). An 
additional aspect is the possible need for increased levodopa equivalent dose (LED), as is 
evident in the case series by Antonini et al (2020). Non-oral dopaminergic therapies will also 
need to be considered if swallowing becomes unsafe and nil by mouth is recommended. For 
mild upper respiratory tract infections, over-the-counter cough and cold remedies are often 
used. However, in some cases such drugs may interact with monoamine A oxidase inhibitors 
(Rasagiline, Selegiline, Safinamide) so a discussion with the pharmacist or phone 
consultation with their PD specialist service may be required to ensure that there are no 
adverse events. In view of the high rate of resistance – although no longer recommended for 
4 
 
treatment of influenza – the antiviral drug Amantadine, used to treat dyskinesia in PD, has 
been cited as a drug of potential interest, among other adamantanes (Torres et al, 2007). At 
this time, there is no data on the safety and efficacy of Amantadine and it has not been 
tested to determine if it is a potentially useful treatment in people with PD infected with 
COVID-19, and should be used with caution due its side effect profile (Cimolai, 2020).  
 
The hidden impact of Covid-19 on people with Parkinson’s 
Staying at home, and isolating from others, has meant dramatic changes to daily routines 
and lifestyles for everyone. Activities previously taken for granted – such as shopping, social 
gatherings, collecting medications, providing childcare or attending a day centre (to name 
but a few) – have all had to stop. Such drastic changes to lifestyles and routines require a 
flexible adaptation to new circumstances, which is a cognitive operation that depends on 
normal dopaminergic functioning (Helmich and Bloem, 2020). A very insightful paper by 
Helmich and Bloem (2020) discussed the large body of literature that demonstrates many 
people with PD experience cognitive and motor inflexibility, as a result of nigrostriatal 
dopamine depletion that forms the pathophysiological substrate of PD (Helmich et al, 2009). 
Furthermore, it has been hypothesized that dopamine-dependent adaptation is a 
requirement for successful coping that, when deficient, leads to a sense of loss of control 
and increased psychological stress (Douma and de Kloet, 2020). On top of this, there is also 
the clearly reported indirect possible effects, such as the impact of stress, self-isolation and 
anxiety, as well as the consequences of prolonged immobility due to the lockdown (Helmich 
and Bloem, 2020; Prasad et al, 2020). Helmich and Bloem (2020), also identified that 
increased levels of stress during the COVID-19 pandemic may have several short-term (as 
well as long-term) adverse consequences for people with PD. It is already understood that 
increased psychological stress can temporarily worsen various motor symptoms of PD, such 
as tremor, freezing of gait or dyskinesias (Macht et al, 2007; Prasad et al, 2020; Zach et al, 
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2017), while it reduces the efficacy of dopaminergic medication (Zach et al, 2017). Helmich 
and Bloem (2020) hypothesised there is also the possibility that there will be an increase in 
the number of newly diagnosed people with PD during, or shortly after, the pandemic, as 
increased stress may unmask a latent hypokinetic rigid syndrome, possibly by depleting 
compensatory mechanisms (Djamshidian and Lees, 2014; Snyder et al, 1985; van Wamelen 
et al, 2020b) . 
 
At present, the guidance from the DHSC for healthcare professionals is to avoid all face-to-
face contact, unless there is a clear and urgent need to do so. This means that outpatient 
clinics have been cancelled and the ability to provide standard PD care is being 
compromised by the strain on healthcare systems brought about by this pandemic (Papa et 
al, 2020). Many PD specialist services are using telehealth and telephone-based services to 
continue to monitor and support people with PD, with positive feedback from users. The 
benefits of telehealth are becoming apparent, providing a means to see people with PD 
within their own home, at a time of day that is more suitable and in a more relaxed and 
convenient way than a outpatients clinic appointment would be. For some PD services, 
telehealth is also proving to be more responsive to the needs of people with PD, as they can 
be seen much more quickly if an issue arises, rather than having a long wait to be seen in 
outpatients. In 2019, NHS England published their Long-Term Plan, which committed to 
reducing face-to-face outpatient appointments by a third; with greater use of telehealth and 
telephone-based services, this target may become a reality.  
Conclusion 
At present, it is too early to know what the long-term impacts of COVID-19 will be for people 
with PD and PD specialist services. Until we have additional clinical data available from 
large-scale, register-based observational studies, it seems that ‘young’ people with PD at 
early motor stage without any significant comorbidities may not have high risk for adverse 
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outcomes in case of COVID-19 infection. However, frail elderly older people with PD , with 
advanced motor disease, comorbidities or undertaking advanced therapies may, indeed, be 
a ‘high-risk’ group. It is, therefore, important that we use this unique opportunity to monitor 
and then understand how the pandemic influences the course of PD. Technologies such as 
wearable sensors or biological biomarkers could provide important data (Helmich and 
Bloem, 2020). It is also a time for PD services to examine and reflect on any new ways of 




• All people with PD fall into the vulnerable group, with potential for severe illness if 
they contract COVID-19; older people with multiple comorbidities may be particularly 
at risk 
• In acutely ill patients, non-oral dopaminergic treatment strategies need to be 
implemented 
• Rigidity of respiratory muscles as well as impaired cough reflex increases the risk of 
developing pneumonia or potentially fatal respiratory failure 
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